MedTrace Logo

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

NCT05041309 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-05-14

No results posted yet for this study

Summary

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.

Conditions

  • Solid and Hematological Malignancies

Interventions

BIOLOGICAL

Axicabtagene Ciloleucel

No investigational product will be administered

BIOLOGICAL

Brexucabtagene Autoleucel

No investigational product will be administered

BIOLOGICAL

Anitocabtagene autleucel

No investigational product will be administered

BIOLOGICAL

KITE-753

No investigational product will be administered

BIOLOGICAL

KITE-197

No investigational product will be administered

BIOLOGICAL

KITE-363

No investigational product will be administered

Sponsors & Collaborators

  • Kite, A Gilead Company

    lead INDUSTRY

Principal Investigators

  • Kite Study Director · Kite, A Gilead Company

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2040-12-31
Completion
2040-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05041309 on ClinicalTrials.gov